Clobenpropit: Difference between revisions
Content deleted Content added
m →See also: adjust link |
m refine |legal status= (via JWB) |
||
Line 6: | Line 6: | ||
| tradename = |
| tradename = |
||
| pregnancy_category = |
| pregnancy_category = |
||
| |
| legal_US = Investigative new drug |
||
| routes_of_administration = |
| routes_of_administration = |
||
Revision as of 16:12, 25 February 2017
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H17ClN4S |
Molar mass | 308.83 g/mol g·mol−1 |
3D model (JSmol) | |
|
Clobenpropit is a histamine H3 receptor antagonist.[1] It has neuroprotective effects via stimulation of GABA release in the brain.[2]
See also
References
- ^ Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P (2007). "The human histamine H3 receptor couples to GIRK channels in Xenopus oocytes". European Journal of Pharmacology. 567 (3): 206–210. doi:10.1016/j.ejphar.2007.04.032. PMID 17537431.
- ^ Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007). "The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons". European Journal of Pharmacology. 563 (1–3): 117–123. doi:10.1016/j.ejphar.2007.01.069. PMID 17350613.